Products
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 010808 | AS703026 | 1236699-92-5 | 98% |  |
| AS703026 is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) | ||||
| 010803 | AZ505 | 1035227-43-0 | 98% |  |
| AZ505 is a potent and highly selective inhibitor of the oncogenic protein SMYD2(IC50= | ||||
| 010428 | AG-L-59687 | 793035-88-8 | 98% |  |
| Coming soon! | ||||
| 010422 | AG1024 | 65678-07-1 | 98% |  |
| AG-1024 inhibits IGF-1R autophosphorylation with IC50 of 7 M, less potent to IR with | ||||
| 010418 | Almotriptan | 154323-57-6 | 98% |  |
| Almotriptan is a 5-HT1B/1D-receptor agonist used to treat migraine. | ||||
| 010410 | AM630 | 164178-33-0 | 98% |  |
| AM630 is a selectivity CB2 antagonist with Ki of 31.2 nM; > 150 fold selectivity o | ||||
| 123019 | AZD-8055 | 1009298-09-2 | 98% |  |
| AZD-8055 is an inhibitor of the mammalian target of rapamycin (mTOR) with potential a | ||||
| 123016 | Amuvatinib | 850879-09-3 | 98% |  |
| Amuvatinib is a potent and multi-targeted inhibitor of c-Kit, PDGFR and Flt3 with IC5 | ||||
| 123009 | AR-42 | 935881-37-1 | 98% |  |
| AR-42 is a novel, oral cancer therapy currently in early clinical development. | ||||
| 123006 | A-966492 | 934162-61-5 | 98% |  |
| A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 n | ||||
| 122942 | AMG 487 | 473719-41-4 | 98% |  |
| AMG 487 is a small molecule antagonist of the chemokine receptor CXCR3. | ||||
| 122931 | Atosiban acetate | 90779-69-4 | 98% |  |
| Atosiban is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/ | ||||
| 122926 | AST-1306 | 897383-62-9 | 98% |  |
| AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and | ||||
| 122925 | AZD8186 | 1627494-13-6 | 98% |  |
| AZD8186 is an isoform-specific small-molecule PI3K inhibitor, potently inhibits PI3K | ||||
| 122906 | AG-120 | 1448346-63-1 | 98% |  |
| AG-120 is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), wi | ||||
| 122902 | AZD-5423 | 1034148-04-3 | 98% |  |
| Coming soon! | ||||
| 122843 | A 83-01 | 909910-43-6 | 98% |  |
| A 83-01 is a selective inhibitor of TGF- type I receptor ALK5 kinase, type I activin/ | ||||
| 122842 | AM251 | 183232-66-8 | 98% |  |
| AM251 is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 3 | ||||
| 122838 | AZD2858 | 486424-20-8 | 98% |  |
| AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, inhibits tau phosphoryl | ||||
| 122824 | Adjudin | 252025-52-8 | 98% |  |
| Adjudin is a drug which is under development as a potential non-hormonal male contrac | ||||
| 122822 | AdipoRon | 924416-43-3 | 98% |  |
| AdipoRon is a novel small-molecule AdipoR agonist; binds to both AdipoR1(Kd= 1.8 uM) | ||||
| 122407 | Anamorelin | 249921-19-5 | 98% |  |
| Anamorelin is a synthetic orally active ghrelin receptor agonist which is under devel | ||||
| 122303 | Atorvastatin sodium | 134523-01-6 | 98% |  |
| Atorvastatin has the potential to ameliorate arsenic-induced vascular dysfunction and | ||||
| 122211 | Amrubicin | 110267-81-7 | 98% |  |
| Amrubicin is a novel anthracycline derivative for treatment of bladder carcinoma. | ||||
| 122210 | AG 490 | 134036-52-5 | 98% |  |
| AG-490 is a tyrosine kinase inhibitor of JAK2, EGFR, and Neu that belongs to the fami | ||||
| 121804 | APD597 | 897732-93-3 | 98% |  |
| APD597 is a potent and selective GPR119 agonist, which is potential useful for the tr | ||||
| 121434 | AT-101 | 90141-22-3 | 98% |  |
| AT-101 is the orally bioavailable the R-(-) enantiomer of gossypol with potential ant | ||||
| 120701 | 4-Aminobenzeneboronic Acid Hydrochloride | 80460-73-7 | 98% |  |
| Coming soon! | ||||
| 120409 | Alendronate sodium trihydrate | 121268-17-5 | 98% |  |
| Coming soon! | ||||
| 120408 | Ambroxol hydrochloride | 23828-92-4 | 98% |  |
| Coming soon! | ||||